# Annexon Inc. (ANNX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.87, market value $923 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Annexon Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.6×**. The shares trade at 4.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -20.9%** (5-yr avg -28.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -97.7%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -32.7%**. Earnings per share fell 32.7%.

## Financial health
- **Current ratio: 5.68** (quick 5.68). Current assets cover the next year's liabilities 5.68 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Annexon Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (7 analysts). 7 analysts cover Annexon Inc.; the consensus is buy, with an average price target of $14.71 (+202% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 126.5%** (YTD -3.0%, 3-mo -7.9%). The shares are up 126.5% over twelve months including dividends.
- **From 52-week high: -32.2%** (131.9% above the low). Trading 32% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): 1.79** (volatility 78%). Beta of 1.79 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ANNX · Page: https://foliofundamentals.com/stocks/annx

Not investment advice.